Cross-Border Recovery: US Medical Visa Approvals for Chinese IVF Patients Jump 50% in Q1 2026
【Abstract】: Data from major cross-border agencies indicates a "Thaw" in US-China medical travel. Approvals for B-2 visas cited for "Medical Treatment" have risen by 50% compared to Q1 2025. High-Net-Worth Individuals (HNWIs) are returning to California and New York specifically for gender selection (PGT-A/M) and surrogacy services, which remain legally restricted in Asia.
Business Insight: The premium segment is bifurcating: mass-market patients go to Southeast Asia for cost, while elite patients return to the US for "legal flexibility" and "tech supremacy." Agencies should restart their high-end US tour packages, focusing on legal compliance and concierge services for the ultra-wealthy.
【Keywords】: #USIVF #MedicalVisa #CrossBorderHealthcare
